Abstract
Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 493-502 |
| Number of pages | 10 |
| Journal | Journal of Nuclear Medicine |
| Volume | 26 |
| Issue number | 5 |
| State | Published - 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
Cite this
Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. / Goodwin, D. A.; Meares, C. F.; McCall, M. J.; Haseman, M. K.; McTigue, M.; Diamanti, C. I.; Chaovapong, W.
In: Journal of Nuclear Medicine, Vol. 26, No. 5, 1985, p. 493-502.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse
AU - Goodwin, D. A.
AU - Meares, C. F.
AU - McCall, M. J.
AU - Haseman, M. K.
AU - McTigue, M.
AU - Diamanti, C. I.
AU - Chaovapong, W.
PY - 1985
Y1 - 1985
N2 - Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.
AB - Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.
UR - http://www.scopus.com/inward/record.url?scp=0022404004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022404004&partnerID=8YFLogxK
M3 - Article
C2 - 3921673
AN - SCOPUS:0022404004
VL - 26
SP - 493
EP - 502
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 5
ER -